Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | SHBG | P04278 | 1/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.81 |
| ▸ | RAB9A | P51151 | 3/20 | 0.81 |
| ▸ | MAPT | P10636 | 3/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.81 |
| ▸ | NPC1 | O15118 | 2/20 | 0.81 |
| ▸ | HTT | P42858 | 2/20 | 0.81 |
| ▸ | GAA | P10253 | 1/20 | 0.81 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | ATM | Q13315 | 1/20 | 0.73 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.69 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30503014 | 1.00 | ESR1 (1.00) | ESR1SHBGESR2LMNARAB9A | |
| SCHEMBL30204024 | 0.90 | LMNA (1.00) | ESR1SHBGESR2LMNARAB9A | |
| SCHEMBL22672221 | 0.90 | ESR1 (0.81) | ESR1SHBGESR2LMNARAB9A | |
| SCHEMBL3820741 | 0.90 | ESR1 (0.81) | ESR1SHBGESR2LMNARAB9A | |
| SCHEMBL3958571 | 0.90 | LMNA (1.00) | ESR1SHBGESR2LMNARAB9A | |
| SCHEMBL2331741 | 0.90 | LMNA (1.00) | ESR1SHBGESR2LMNARAB9A | |
| SCHEMBL3586687 | 0.90 | ESR1 (0.81) | ESR1SHBGESR2LMNARAB9A | |
| SCHEMBL38652384 | 0.90 | ESR1 (0.81) | ESR1SHBGESR2LMNARAB9A | |
| SCHEMBL29514772 | 0.90 | ESR1 (0.81) | ESR1SHBGESR2LMNARAB9A | |
| SCHEMBL146018 | 0.89 | ESR1 (0.80) | ESR1SHBGESR2LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116332893-A | Synthesis method of daidzein | 广东工业大学 | 2023-06-27 | — | — | CN | claimed |
| US-6334998-B1 | PRETREATMENT WITH ESTROGEN COMPOUND, FOR EXAMPLE, ESTROGENIC ISOFLAVONE, PREVENTS PATHOLOGIC CONDITIONS ASSOCIATED WITH AMYOTROPHIC LATERAL SCLEROSIS AND DELAYS DISEASE ONSET IN INDIVIDUALS AT HIGH RISK | PARKER HUGHES INSTITUTE | 2002-01-01 | — | — | US | claimed |
| EP-1158975-A1 | USE OF ISOFLAVONES AND/OR AFRICAN PLUM EXTRACTS FOR PREPARING A COMPOSITION DESIGNED TO INHIBIT 5$G(A)-REDUCTASE ACTIVITY, IN PHARMACOLOGY PARTICULARLY IN DERMATOLOGY, IN COSMETICS AND AS FOOD ADDITIVE | Laboratoires Pharmascience (FR) | 2001-12-05 | — | — | EP | claimed |
| WO-2001052840-A1 | USE OF ISOFLAVONES AND/OR AFRICAN PLUM EXTRACTS FOR PREPARING A COMPOSITION DESIGNED TO INHIBIT 5$G(A)-REDUCTASE ACTIVITY, IN PHARMACOLOGY PARTICULARLY IN DERMATOLOGY, IN COSMETICS AND AS FOOD ADDITIVE | LABORATOIRES PHARMASCIENCE (FR) | 2001-07-26 | — | — | WO | claimed |
| WO-2001041751-A2 | PHYTOESTROGENS FOR TREATING ALS | PARKER HUGHES INSTITUTE (US) | 2001-06-14 | — | — | WO | claimed |
| CN-116332893-A | Synthesis method of daidzein | 广东工业大学 | 2023-06-27 | — | — | CN | disclosed |
| CN-116332893-A | Synthesis method of daidzein | 广东工业大学 | 2023-06-27 | — | — | CN | disclosed |
| WO-2023278394-A1 | POLYCATIONIC SALTS OF PHENOLIC COMPOUNDS AND USES THEREOF | FIRMENICH INCORPORATED (US) | 2023-01-05 | — | — | WO | disclosed |
| US-10548903-B2 | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM | ENDORECHERCHE, INC. (CA) | 2020-02-04 | — | — | US | disclosed |
| US-20190269697-A1 | A METHOD OF TREATING AND PREVENTING LOSS OF COGNITION | ENDORECHERCHE, INC. (CA) | 2019-09-05 | — | — | US | disclosed |
| US-20190269696-A1 | METHOD OF PREVENTING ALZHEIMIER'S DISEASE | ENDORECHERCHE, INC. (CA) | 2019-09-05 | — | — | US | disclosed |
| US-10342805-B2 | Treatment of Alzheimer's disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators | ENDORECHERCHE, INC. (CA) | 2019-07-09 | — | — | US | disclosed |
| US-6334998-B1 | PRETREATMENT WITH ESTROGEN COMPOUND, FOR EXAMPLE, ESTROGENIC ISOFLAVONE, PREVENTS PATHOLOGIC CONDITIONS ASSOCIATED WITH AMYOTROPHIC LATERAL SCLEROSIS AND DELAYS DISEASE ONSET IN INDIVIDUALS AT HIGH RISK | PARKER HUGHES INSTITUTE | 2002-01-01 | — | — | US | disclosed |
| EP-1158975-A1 | USE OF ISOFLAVONES AND/OR AFRICAN PLUM EXTRACTS FOR PREPARING A COMPOSITION DESIGNED TO INHIBIT 5$G(A)-REDUCTASE ACTIVITY, IN PHARMACOLOGY PARTICULARLY IN DERMATOLOGY, IN COSMETICS AND AS FOOD ADDITIVE | Laboratoires Pharmascience (FR) | 2001-12-05 | — | — | EP | disclosed |
| WO-2001068634-A1 | 4-FLUOROALKYL-2H-BENZOPYRANS WITH ANTI-ESTROGENIC ACTIVITY | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001052840-A1 | USE OF ISOFLAVONES AND/OR AFRICAN PLUM EXTRACTS FOR PREPARING A COMPOSITION DESIGNED TO INHIBIT 5$G(A)-REDUCTASE ACTIVITY, IN PHARMACOLOGY PARTICULARLY IN DERMATOLOGY, IN COSMETICS AND AS FOOD ADDITIVE | LABORATOIRES PHARMASCIENCE (FR) | 2001-07-26 | — | — | WO | disclosed |
| US-6262270-B1 | HYDROXYPHENYLACETOPHENONE DERIVATIVE IS REACTED WITH N-ETHOXYBENZYL PIPERIDINE COMPOUND IN PRESENCE OF PIPERIDINE AND HINDERED AMINE BASE AND ALKANOL TO PRODUCE PURE ANTIESTROGEN COMPOUND | SCHERING CORPORATION | 2001-07-17 | — | — | US | disclosed |
| WO-2001041751-A2 | PHYTOESTROGENS FOR TREATING ALS | PARKER HUGHES INSTITUTE (US) | 2001-06-14 | — | — | WO | disclosed |
| US-5151420-A | Cardiovascular disorders | ORION CORPORATION/ORION PHARMACEUTICA (FI) | 1992-09-29 | — | — | US | disclosed |
| EP-0359439-A1 | Substituted pyridazinones | ORION-YHTYMÄ OY (FI) | 1990-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190269697-A1 | A METHOD OF TREATING AND PREVENTING LOSS OF COGNITION | SHBG, BRCA1, CYP19A1 | ESR1 15/4885SHBG 1/4885ESR2 5/4885 |
| US-20190269696-A1 | METHOD OF PREVENTING ALZHEIMIER'S DISEASE | BRCA1, SHBG, CYP19A1 | ESR1 11/4885SHBG 2/4885ESR2 5/4885 |
| US-10342805-B2 | Treatment of Alzheimer's disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators | BRCA1, SHBG, CYP19A1 | ESR1 5/4885SHBG 2/4885ESR2 6/4885 |
| US-10548903-B2 | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM | SHBG, CYP19A1, AR | ESR1 52/4885SHBG 1/4885ESR2 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.